<h4>AmplifyBio Celebrates One Year Since Launch With an Expansion of Capabilities and Capacity and a New Site</h4>
In the first year, AmplifyBio achieved the primary strategic goals of increasing capacity by 50% and adding a state-of-the-art analytics laboratory. Assessing biodistribution, gene expression, vector integration, and monitoring immune responses alongside preclinical work provide the data necessary to modify study designs, improve efficiencies, compress timelines, and reduce costs.
PLEASANTON, CA — May 3, 2022 – Veeva Systems (NYSE: VEEV) today announced that AmplifyBio is building a foundation for advanced quality, study execution, and reporting with Veeva Vault Quality Suite. Using a modern quality system with built-in industry best practices, the company will streamline and automate processes to increase the efficiency of its preclinical drug testing. “At […]
AmplifyBio will be exhibiting at the Society of Toxicology Meeting in San Diego, California: May 27th – May 31st. Like many people, the team at AmplifyBio is looking forward to getting out and meeting with customers and colleagues in person again. AmplifyBio is a leading preclinical CRO focused on toxicology, safety and pharmacology testing to advance […]